Nicholas Short, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the findings of a Phase Ib/II multi-arm study (NCT03390296) which investigated various combinations of novel agents in relapsed/refractory acute myeloid leukemia (AML). The trial had 5 arms: azacitidine (aza) + venetoclax (VEN) + gemtuzumab ozogamicin (GO; a anti-CD33 monoclonal antibody), aza + VEN + avelumab (PD-1R mAb), AZA + avelumab + GO, OX40 agonist monoclonal antibody, and glasdegib (SMO inhibitor) + GO. All 3 arms testing novel triplet combinations demonstrated safety and efficacy and thus, accrual to his cohorts will continue. The cohorts treated with OX40 agonist and glasdegib + GO showed no responses, although the patient numbers were small. This trial design testing multiple novel combinations may be a more rapid method of identifying possible feasible regimens as an increasing number of therapeutics become available. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Consulting fees: Takeda Oncology, AstraZeneca Research funding: Takeda Oncology, Astellas Pharma Inc. Honoraria: Amgen